Vasomotor Symptoms of Menopause Treatment Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast – 2022 to 2028

The Vasomotor Symptoms of Menopause Treatment Market is anticipated to hold a value of USD 8,189 Million by 2028 and is expected to register a CAGR of 7% during the assessment period of 2022 to 2028.

Vasomotor Menopausal Symptoms (VMS) are usually associated with flashing or flushing (HF) and night sweats, which are more prevalent in women during menopause. It is characterized by fluctuations and hormonal disturbances caused by sudden changes in body temperature. The exact etiology is unclear. Menopausal women seek treatment more often.

Market Segments

By Therapy

• Contraceptives
• Estrogen-Progesterone therapy
• Compound hormone therapy
• OTC hormones

Key Players

• Allergan (Ireland)
• Eli Lily and Company (US)
• Emcure Pharmaceuticals Ltd (India)
• Merck & Co., Inc. (US)
• Mithra Pharmaceuticals (Belgium)
• Novartis AG (Switzerland)
• Novo Nordisk A/S (Denmark)
• Pfizer Inc. (US)
• Teva Pharmaceuticals (Israel)
• TherapeuticsMD, Inc. (US)
• Procter & Gamble (US)
• EndoCeutics, Inc. (Canada)
• Amag Pharmaceuticals (US)

Scope of the Report

The research study analyzes the global Vasomotor Symptoms of Menopause Treatment industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:

Recent Developments

o Market Overview and growth analysis
o Import and Export Overview
o Volume Analysis
o Current Market Trends and Future Outlook
o Market Opportunistic and Attractive Investment Segment

Geographic Coverage

o North America Market Size and/or Volume
o Latin America Market Size and/or Volume
o Europe Market Size and/or Volume
o Asia-Pacific Market Size and/or Volume
o Rest of the world Market Size and/or Volume

Key Questions Answered by Vasomotor Symptoms of Menopause Treatment Market Report

1. What was the Vasomotor Symptoms of Menopause Treatment Market size in 2020 and 2021; what are the estimated growth trends and market forecast (2022-2028).

2. What will be the CAGR of Vasomotor Symptoms of Menopause Treatment Market during the forecast period (2022-2028)?
3. Which segments (product type/applications/end-user) were most attractive for investments in 2022? How these segments are expected to grow during the forecast period (2022-2028).
4. Which manufacturer/vendor/players in the Vasomotor Symptoms of Menopause Treatment Market was the market leader in 2020?
5. Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.